MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) CEO Erez Aminov Sells 55,410 Shares

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) CEO Erez Aminov sold 55,410 shares of the business’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $1.39, for a total transaction of $77,019.90. Following the completion of the sale, the chief executive officer now directly owns 1,105,790 shares of the company’s stock, valued at $1,537,048.10. This represents a 4.77 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

MIRA Pharmaceuticals Price Performance

Shares of NASDAQ:MIRA opened at $1.27 on Thursday. MIRA Pharmaceuticals, Inc. has a 1 year low of $0.51 and a 1 year high of $5.01. The stock’s 50-day moving average is $1.34 and its 200 day moving average is $1.32. The company has a market cap of $21.03 million, a PE ratio of -2.27 and a beta of 3.09.

MIRA Pharmaceuticals (NASDAQ:MIRA) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.04. Analysts expect that MIRA Pharmaceuticals, Inc. will post -0.6 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on MIRA shares. Ascendiant Capital Markets began coverage on MIRA Pharmaceuticals in a research note on Monday, August 5th. They issued a “buy” rating and a $11.00 target price for the company. RODMAN&RENSHAW upgraded MIRA Pharmaceuticals to a “strong-buy” rating in a research report on Monday, September 30th. Finally, Rodman & Renshaw began coverage on shares of MIRA Pharmaceuticals in a report on Monday, September 30th. They issued a “buy” rating and a $17.00 target price on the stock.

Institutional Inflows and Outflows

An institutional investor recently raised its position in MIRA Pharmaceuticals stock. Virtu Financial LLC boosted its position in MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) by 330.2% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 63,055 shares of the company’s stock after purchasing an additional 48,397 shares during the quarter. Virtu Financial LLC owned approximately 0.43% of MIRA Pharmaceuticals worth $69,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 35.16% of the company’s stock.

About MIRA Pharmaceuticals

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.